Case Reports|Volume 10, Issue 0|pp 44—53

Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma

Mohamed A. Gouda, Maria A. Zarzour, Ara A. Vaporciyan, Kalevi Kairemo, Hubert H. Chuang, Vivek Subbiah

Received: June 8, 2023Accepted: August 21, 2023Published: September 20, 2023

https://doi.org/10.18632/oncoscience.587

Abstract

Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma. In this case report, we discuss the case of a patient with a EWSR1-NFATC2 fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years. We also review the literature on EWSR1-NFATC2 translocation-associated sarcomas and use of pazopanib in bone sarcomas.